Urinary tract endometriosis is rare, especially suburethral endometriosis with symptoms of dysuria and urgency is very rare. We report a case of successful surgically treated suburethral endometriosis through the Retzius space.
Dysuria ; Endometriosis ; Female ; Urinary Tract

Malignant mesothelioma is a rare neoplasm and arises from the serosal lining of the pleural, peritoneal and pericardial cavities. The median survival rang from 5 to 12 months, mainly because of lack of effective treatment. The incidence is approximately one per 1,000,000 and peritoneal mesothelioma represents one fourth of all mesotheliomas. There is a relationship between mesothelioma and asbestos exposure, but non-asbestos related cases were reported. Treatments of malignant mesothelioma are cytoreductive surgery and adjuvant chemotherapy, but current treatment options are unsatisfactory. We report two cases of malignant mesothelioma of the peritoneum and pericardium treated by operation and adjuvant chemotherapy with a brief review of literature.
Asbestos ; Chemotherapy, Adjuvant ; Incidence ; Mesothelioma ; Pericardium ; Peritoneum

Malignant mesothelioma is a rare neoplasm and arises from the serosal lining of the pleural, peritoneal and pericardial cavities. The median survival rang from 5 to 12 months, mainly because of lack of effective treatment. The incidence is approximately one per 1,000,000 and peritoneal mesothelioma represents one fourth of all mesotheliomas. There is a relationship between mesothelioma and asbestos exposure, but non-asbestos related cases were reported. Treatments of malignant mesothelioma are cytoreductive surgery and adjuvant chemotherapy, but current treatment options are unsatisfactory. We report two cases of malignant mesothelioma of the peritoneum and pericardium treated by operation and adjuvant chemotherapy with a brief review of literature.
Asbestos ; Chemotherapy, Adjuvant ; Incidence ; Mesothelioma ; Pericardium ; Peritoneum

No abstract available.
Hyaluronic Acid*

OBJECTIVE: To compare the differences in the second trimester Quad test markers in patients who subsequently developed preeclampsia depending on the disease onset time and the presence of fetal growth restriction (FGR). METHODS: A retrospective study was carried out on 66 women with severe preeclampsia and 345 controls who were delivered at Dong-A University hospital and Ilsin Christian Hospital from January 2006 to December 2008. Severe preeclampsia patients were grouped according to with (n=30) or without (n=36) FGR. Severe preeclampsia patients were also grouped according to early onset (n=16) or late onset (n=50) The levels of the second trimester human chorionic gonadotropin (hCG), inhibin-A, unconjugated estriol (uE3), alpha-fetoprotein (AFP) were compared in each group. RESULTS: In the pregnancies that subsequently developed severe preeclampsia, the second trimester hCG, inhibin-A and AFP were significantly higher than the controls. We found that levels of hCG, inhibin-A in severe preeclampsia complicated by FGR were significantly higher than those without FGR. We also found that levels of AFP and inhibin-A in early onset severe preeclampsia were significantly higher than late onset severe preeclampsia. CONCLUSION: The levels of second trimester Quad test markers in patients that subsequently developed severe preeclampsia were different according to with or without FGR and onset time.
Adenine ; alpha-Fetoproteins ; Carbamates ; Chorionic Gonadotropin ; Deoxycytidine ; Drug Combinations ; Estriol ; Female ; Fetal Development ; Humans ; Organophosphonates ; Pre-Eclampsia ; Pregnancy ; Pregnancy Trimester, Second ; Quinolones ; Retrospective Studies ; Thiazoles ; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination

BACKGROUND: Psychosocial stress and stressful events in life have been reported to be closely related to the onset and acute exacerbation of some dermatologic disorders, such as alopecia areata, psoriasis, seborrheic dermatitis and atopic dermatitis. However, the nature of the association between stress and dermatologic disorders remains unclear. OBJECTIVE: The purpose of this study is to determine the relation of stress and the onset and exacerbation of dermatologic disorders. Furthermore we studied whether the coping strategies to stress are related to dermatologic disorders. METHOD: We examined 30 patients with alopecia areata, 30 patients with androgenetic alopecia who visited Dept. of Dermatology, Chung-Ang University Hospital and a control group of 30 who visited our clinic at the same time for tinea pedis and onychomycosis, which are supposed not to be related to stress. For the evaluation of stress we used questionares of 'Scale of Life Events' and 'Multidimensional Coping Scale'. RESULT: 1) The score of life event stress in the alopecia areata group was significantly higher than that of the normal control group. The score of life event stress in androgenetic alopecia was higher than that of the normal control group with no statistical significance. 2) In the aspect of coping strategies, the alopecia areata group was significantly higher than the normal control group at the passive withdrawal and fatalism, while in the normal control group, emotional pacification, positive comparison and religious seeking tended to be higher than the alopecia areata group. In the androgenetic alopecia group, no significant pathologic coping strategies were found compared with the control. CONCLUSION: These findings suggest that the psychosocial stress may play a role in the pathogenesis of alopecia areata and androgenetic alopecia. But to clarify the exact role of stress, further studies about biological parameters of physiologic changes to stress are needed in the future.
Alopecia Areata* ; Alopecia* ; Dermatitis, Atopic ; Dermatitis, Seborrheic ; Dermatology ; Humans ; Life Change Events ; Onychomycosis ; Psoriasis ; Tinea Pedis

The coronavirus disease 2019 (COVID-19) pandemic has caused more than 100 million infections and 2 million deaths worldwide. In up to 20% of cases, COVID-19 infection can take a severe, life-threatening course. Therefore, preventive measures such as mask-wearing, hand hygiene, and social distancing are important. COVID-19 vaccines that use novel vaccine technology can prevent up to 95% of infections. However, the uncertainty regarding the efficacy and safety of vaccination in patients with autoimmune inflammatory rheumatic disease (AIIRD), who are immunocompromised due to underlying immune dysfunction and concomitant immunosuppressive treatment, warrants clear guidance. A task force of the Korean College of Rheumatology formulated a set of vaccination guidance based on the currently available data and expert consensus. The currently available COVID-19 vaccines are considered to be safe and effective. Every patient with AIIRD should receive one of the available COVID-19 vaccines unless contraindicated for medical reasons such as prior allergy/anaphylaxis to the COVID-19 vaccine or its components. Patients should continue immunosuppressive treatment for their underlying AIIRD, including biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). Corticosteroids should be reduced to the lowest dose possible without aggravating the AIIRD. To improve the vaccine response, methotrexate can be withheld for 1–2 weeks after each vaccination, and the timing of rituximab and abatacept infusion should be adjusted if clinically acceptable.Rheumatologists should play a leading role in educating and vaccinating patients with AIIRD.

The coronavirus disease 2019 (COVID-19) pandemic has caused more than 100 million infections and 2 million deaths worldwide. In up to 20% of cases, COVID-19 infection can take a severe, life-threatening course. Therefore, preventive measures such as mask-wearing, hand hygiene, and social distancing are important. COVID-19 vaccines that use novel vaccine technology can prevent up to 95% of infections. However, the uncertainty regarding the efficacy and safety of vaccination in patients with autoimmune inflammatory rheumatic disease (AIIRD), who are immunocompromised due to underlying immune dysfunction and concomitant immunosuppressive treatment, warrants clear guidance. A task force of the Korean College of Rheumatology formulated a set of vaccination guidance based on the currently available data and expert consensus. The currently available COVID-19 vaccines are considered to be safe and effective. Every patient with AIIRD should receive one of the available COVID-19 vaccines unless contraindicated for medical reasons such as prior allergy/anaphylaxis to the COVID-19 vaccine or its components. Patients should continue immunosuppressive treatment for their underlying AIIRD, including biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). Corticosteroids should be reduced to the lowest dose possible without aggravating the AIIRD. To improve the vaccine response, methotrexate can be withheld for 1–2 weeks after each vaccination, and the timing of rituximab and abatacept infusion should be adjusted if clinically acceptable.Rheumatologists should play a leading role in educating and vaccinating patients with AIIRD.